Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first ...

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

Quest Diagnostics, a cancer treatment laboratory in Lewisville, received a proclamation from Lewisville City Council after ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoringMORRISVILLE, N.C.--(BUSINESS ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

A looming revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster biotech stocks like Guardant Health, Natera and Exact Sciences. And all it takes is a little blood.

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...